Holen Sie sich die Stockscreener-App
11.21
0.63%
0.0716
Schlusskurs vom Vortag:
$11.14
Offen:
$11.2
24-Stunden-Volumen:
168.76K
Relative Volume:
0.46
Marktkapitalisierung:
$628.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-72.89M
KGV:
-4.5949
EPS:
-2.44
Netto-Cashflow:
$-68.47M
1W Leistung:
+0.27%
1M Leistung:
+0.27%
6M Leistung:
-27.49%
1J Leistung:
+41.55%
1-Tages-Spanne:
$11.04
$11.41
1-Wochen-Bereich:
$10.27
$11.57
52-Wochen-Spanne:
$4.26
$16.90
Astria Therapeutics Inc Stock (ATXS) Company Profile
Firmenname
Astria Therapeutics Inc
Sektor
Branche
Telefon
617-349-1971
Adresse
22 BOSTON WHARF ROAD, BOSTON
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-28 | Eingeleitet | Evercore ISI | Outperform |
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
ClariVest Asset Management LLC Makes New $731,000 Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Where are the Opportunities in (ATXS) - Stock Traders Daily
Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 5.9% - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Panagora Asset Management Inc. - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Is Astria Therapeutics Inc (ATXS) worth investing in despite its overvalued state? - US Post News
Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Significant Growth in Short Interest - MarketBeat
Astria Therapeutics to Present at Upcoming Bradykinin Symposium - Business Wire
Astria Therapeutics to Present at Upcoming Bradykinin Symposium - StockTitan
Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire
(ATXS) Trading Advice - Stock Traders Daily
Analyzing Astria Therapeutics Inc (ATXS) After Recent Trading Activity - Knox Daily
Astria Therapeutics (ATXS) – Investment Analysts’ Weekly Ratings Updates - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.20 Consensus PT from Analysts - Defense World
Price T Rowe Associates Inc. MD Buys Shares of 14,203 Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Upgraded at Evercore ISI - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Forecasted to Post Q3 2024 Earnings of ($0.45) Per Share - Defense World
Q3 2024 EPS Estimates for Astria Therapeutics, Inc. Decreased by HC Wainwright (NASDAQ:ATXS) - MarketBeat
Q3 2024 EPS Estimates for Astria Therapeutics, Inc. Decreased by HC Wainwright (NASDAQ:ATXS) - Defense World
Astria Therapeutics (NASDAQ:ATXS) Trading Down 2.8% - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Given Outperform Rating at Wedbush - Defense World
Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $26.00 at Oppenheimer - Defense World
Astria Therapeutics (NASDAQ:ATXS) Releases Earnings Results, Misses Estimates By $0.05 EPS - Defense World
Astria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC Wainwright - Defense World
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up Following Analyst Upgrade - Defense World
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up on Analyst Upgrade - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Given "Outperform" Rating at Wedbush - MarketBeat
Astria Therapeutics stock target raised by Oppenheimer on clinical progress - Investing.com Canada
Astria Therapeutics partners with Ypsomed for autoinjector development By Investing.com - Investing.com Australia
Astria Therapeutics (NASDAQ:ATXS) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
TD Cowen keeps Buy rating on Astria Therapeutics stock, highlights STAR-0215's Q6M dosing - Investing.com UK
Astria Therapeutics taps Ypsomed’s autoinjector for hereditary angioedema drug delivery - Yahoo Finance
Astria Therapeutics (NASDAQ:ATXS) PT Raised to $26.00 - MarketBeat
Astria Therapeutics stock target raised by Oppenheimer on clinical progress - Investing.com UK
ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Astria Therapeutics partners with Ypsomed for autoinjector development - Investing.com
Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update - Business Wire
Astria Therapeutics reports Q2 EPS (43c), consensus (38c) - TipRanks
Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema - StockTitan
Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema - Yahoo Finance
Vanguard Group Inc. Acquires 480,184 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Vanguard Group Inc. Raises Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference - Business Wire
Tidal Investments LLC Buys New Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update - Defense World
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up to $11.93 - Defense World
Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Decreases By 5.7% - MarketBeat
Finanzdaten der Astria Therapeutics Inc-Aktie (ATXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Astria Therapeutics Inc-Aktie (ATXS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morabito Christopher | Chief Medical Officer |
Apr 01 '24 |
Sale |
13.59 |
10,000 |
135,939 |
0 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 01 '24 |
Buy |
12.09 |
2,481,350 |
29,999,522 |
4,873,721 |
| Morabito Christopher | Chief Medical Officer |
Jan 29 '24 |
Option Exercise |
3.87 |
9,200 |
35,604 |
9,200 |
| Morabito Christopher | Chief Medical Officer |
Jan 26 '24 |
Option Exercise |
3.87 |
800 |
3,096 |
800 |
| Morabito Christopher | Chief Medical Officer |
Jan 29 '24 |
Sale |
11.15 |
9,200 |
102,552 |
0 |
| Morabito Christopher | Chief Medical Officer |
Jan 26 '24 |
Sale |
11.02 |
800 |
8,812 |
0 |
| PERCEPTIVE ADVISORS LLC | Director |
Dec 21 '23 |
Buy |
6.20 |
740,000 |
4,588,000 |
2,392,371 |
| PERCEPTIVE ADVISORS LLC | Director |
Oct 16 '23 |
Buy |
6.51 |
1,074,608 |
6,999,997 |
1,652,371 |
1.19%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):